Glenmark Therapeutics

Glenmark Therapeutics is the innovative and specialty division of Glenmark Pharmaceuticals, focusing on the development and commercialization of novel therapies in core therapeutic areas such as dermatology, respiratory, and oncology. The company operates as a bridge between high-end R&D and commercial markets, particularly in the United States and Europe, managing a portfolio that includes both proprietary branded products and complex generics. A key highlight of their portfolio is Ryaltris, a fixed-dose combination nasal spray for allergic rhinitis that has achieved global commercial success. Through its affiliate Ichnos Glenmark Innovation (IGI), the company is also advancing a pipeline of multispecific antibodies in oncology and immunology, transitioning from a traditional generic manufacturer to an innovation-led pharmaceutical organization.